Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.11.28.690516

Not every gene is special: one simple rule to control the false discovery rate when analysing high-throughput sequencing data

Dos Santos, S. J.·Murariu, A. C.·Silverman, J. D.·Gloor, G. B.
View original source ↗Export metadata ↓

Abstract

1Differential expression and differential abundance analyses are commonplace in studies employing high-throughput sequencing approaches; however different tools often fail to return comparable results when applied to the same dataset. Most tools employ various normalisations to attempt to correct for technical variation in the count data. Previously, we demonstrated that these normalisations are often inappropriate due to incorrect assumptions regarding the overall scale (i.e. size) of the biological system in question. In this study, we conducted 100 permutation analyses of 10 RNA-seq datasets to show that scale misspecification results in poor control of the false discovery rate by several commonly-used analysis tools. Moreover, we demonstrate that this can be ameliorated by using a scale model in ALDEx2 or ALDEx3 to account for uncertainty around the size of the system scale. We show that there is an inherent trade-off between satisfactory control of false-discovery rates and sensitivity and that no tool offers both. We also quantify how increasing scale uncertainty affects the difference between groups required for a feature to be reported as differentially expressed. Finally, we provide universal guidance on choosing an appropriate amount of scale uncertainty for any type of analysis. Overall, our work highlights the strengths and pitfalls of commonly used tools for differential expression analyses and highlights the choice between sensitivity and false-discovery rate control that all researchers are making when analysing sequencing data.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dos Santos, S. J., Murariu, A. C., Silverman, J. D., Gloor, G. B.. 2025-12-01. Not every gene is special: one simple rule to control the false discovery rate when analysing high-throughput sequencing data. https://doi.org/10.1101/2025.11.28.690516

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗
bioRxiv2026

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗
bioRxiv2026

CryoMV: Structure-Prior-Guided Modeling and Real-Particle Validation of Continuous Conformational Transitions in Cryo-EM

Continuous protein conformations are essential for understanding fundamental biological processes and supporting drug discovery. Although cryo-EM can resolve individual states at high resolution, recovering continuous heterogeneity from 2D particle images remains challenging. High noise, motion blur, and limited structural priors make it difficult to accurately generate and validate high-resolution continuous conformations using raw particle data. Here, we introduce cryoMV, a framework that integrates structure-prior-guided modeling with real-particle validation for continuous conformational transitions. CryoMV uses reference density maps to establish structural anchors and motion priors, models candidate transition paths between selected conformations, and transfers the learned representation to raw 2D cryo-EM particle images. Each candidate conformation is subsequently evaluated using the estimated particle poses and contrast transfer functions. Supported conformations are reconstructed through raw particle back-projection and assessed using canonical half-maps and Fourier shell correlation. On EMPIAR-10516 and EMPIAR-10345, cryoMV achieves excellent performance in terms of robustness, verifiability, and reconstruction resolution. By incorporating structure-prior modeling and evidence from the raw particles, cryoMV offers an explicit mechanism for assessing whether generated conformations are supported by experimental data and provides a practical approach to reducing model-induced artifacts in continuous cryo-EM heterogeneity analysis.

bioinformatics↗